Table 2.
Absolute number and percentage reduction in inflammatory lesions (FAS)
| Treatment group | Baseline, no. of IL | End of study, no. of IL | Absolute reduction, no. of IL | Percentage reduction, % |
|---|---|---|---|---|
| 2.5% BPO gel (203 cases) | 18 (14–26) | 5 (2–11) | 12*** (8–18) | 72.7*** (46.2–87.5) |
| Difference from placebo | – | −5 | 5 (4–7) | 25.7 (19.2–32.9) |
| 5% BPO gel (203 cases) | 18 (14–26) | 4 (2–9) | 12*** (9–18) | 75.0*** (60.0–85.7) |
| Difference from placebo | – | −5 | 6 (5–8) | 28.0 (21.6–34.9) |
| Placebo | 18 (14–24) | 11 (6–19) | 7 (1–12) | 41.7 (6.3–66.7) |
***Median (interquartile range). Difference from placebo: Hodges–Lehmann estimator (95% confidence intervals). P < 0.001 vs placebo (Wilcoxon two‐sample test). BPO, benzoyl peroxide; FAS, full analysis set; IL, inflammatory lesions.